- Trials with a EudraCT protocol (219)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
219 result(s) found for: West syndrome.
Displaying page 6 of 11.
EudraCT Number: 2014-002666-76 | Sponsor Protocol Number: 200363 | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: An open-label study to characterize the pharmacokinetics and pharmacodynamics of mepolizumab administered subcutaneously in children from 6 to 11 years of age with severe eosinophilic asthma | |||||||||||||
Medical condition: Severe Eosinophilic Asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005198-29 | Sponsor Protocol Number: CB8025-31731-RE | Start Date*: 2021-05-10 | |||||||||||
Sponsor Name:CymaBay Therapeutics, Inc. | |||||||||||||
Full Title: ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000400-26 | Sponsor Protocol Number: 201842 | Start Date*: 2015-12-15 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Ltd | |||||||||||||
Full Title: A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in su... | |||||||||||||
Medical condition: Primary Sjogrens disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003830-17 | Sponsor Protocol Number: ACH228-110 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient... | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000104-15 | Sponsor Protocol Number: CCS1477-02 | Start Date*: 2021-07-29 |
Sponsor Name:CellCentric Ltd | ||
Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies. | ||
Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001758-14 | Sponsor Protocol Number: 201677 | Start Date*: 2015-12-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients with Giant Cell Arteritis | |||||||||||||
Medical condition: Giant Cell Arteritis (GCA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000075-33 | Sponsor Protocol Number: OMS721-IGA-001 | Start Date*: 2018-06-07 |
Sponsor Name:Omeros Corporation | ||
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS – IGAN) | ||
Medical condition: IgA nephropathy (IgAN) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) LT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) BE (Completed) AT (Prematurely Ended) PL (Prematurely Ended) BG (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Prematurely Ended) GR (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-001266-17 | Sponsor Protocol Number: DMD114349 | Start Date*: 2011-08-08 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development LTD | |||||||||||||
Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of GSK2402968 in subjects with Duchenne Muscular Dystrophy | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Ongoing) DE (Completed) GB (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA BG (Prematurely Ended) HU (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001251-40 | Sponsor Protocol Number: MEA115588 | Start Date*: 2012-10-16 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: MEA115588 A randomised, double-blind, double-dummy, placebo-controlled, parallel-group, multi-centre study of the efficacy and safety of mepolizumab adjunctive therapy in subjects with severe uncon... | ||
Medical condition: Subjects with severe, refractory, uncontrolled asthma with elevated blood eosinphils | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2010-022838-85 | Sponsor Protocol Number: MEK114267 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: MEK114267, A Phase III randomized, open-label study comparing GSK1120212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma | |||||||||||||
Medical condition: Advanced or metastatic BRAF V600E/K mutation-positive melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) BE (Completed) CZ (Completed) GR (Completed) NO (Completed) GB (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000502-11 | Sponsor Protocol Number: EKOS-12 | Start Date*: 2016-07-21 |
Sponsor Name:EKOS Corporation | ||
Full Title: Study of the Optimum Duration of Acoustic Pulse Thrombolysis (APT) Procedure in the Treatment of Acute Submassive Pulmonary Embolism (OPTALYSE PE). | ||
Medical condition: Submassive pulmonary embolism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000157-41 | Sponsor Protocol Number: UoL001343 | Start Date*: 2019-06-07 | |||||||||||
Sponsor Name:The University of Liverpool | |||||||||||||
Full Title: NEO21-RS: A phase II randomised study of the cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with oestrogen suppression therapy versus oestrogen suppression therapy alone as neoadj... | |||||||||||||
Medical condition: ER-positive, HER2-negative breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004883-12 | Sponsor Protocol Number: ADA109057 | Start Date*: 2016-12-08 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A 52-week, Randomized, Double-Blind, Parallel-Group Study of Fluticasone Propionate/Salmeterol DISKUS Combination Product (FSC) 250/50 mcg BID and Fluticasone Propionate (FP) DISKUS 250 mcg BID in ... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-003103-27 | Sponsor Protocol Number: UoL001152 | Start Date*: 2017-01-19 |
Sponsor Name:University of Liverpool | ||
Full Title: A proof of concept phase II study of Buparlisib in HER2 positive breast cancer with brain metastasis following HER2 directed monoclonal antibody therapy | ||
Medical condition: HER2-positive breast cancer with brain metastasis | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007149-30 | Sponsor Protocol Number: 4500 | Start Date*: 2009-01-14 | |||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
[...]
1. Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
2. Cambridge Clinical Trials Unit |
|||||||||||||
Full Title: Optimal Treatment of Drug Resistant Hypertension | |||||||||||||
Medical condition: Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002149-36 | Sponsor Protocol Number: G-202-002 | Start Date*: 2012-12-10 | |||||||||||
Sponsor Name:GenSpera, Inc. | |||||||||||||
Full Title: An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients with Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
Medical condition: chemotherapy-naïve metastatic castrate-resistant prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-005040-27 | Sponsor Protocol Number: MDX060-03E | Start Date*: 2006-03-10 | |||||||||||
Sponsor Name:Medarex, Inc. | |||||||||||||
Full Title: An Open-Label, Phase II Extension Study of MDX-060 in Patients with Relapsed or Refractory Hodgkin’s Disease Previously Treated in Protocol MDX060-03 | |||||||||||||
Medical condition: Relapsed or Refractory Hodgkin’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001521-41 | Sponsor Protocol Number: UoL001304 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001032-11 | Sponsor Protocol Number: OMS721-TMA-001 | Start Date*: 2014-09-30 | |||||||||||
Sponsor Name:Omeros Corporation | |||||||||||||
Full Title: A Phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombo... | |||||||||||||
Medical condition: Three forms of thrombotic microangiopathies (TMA): - atypical hemolytic uremic syndrome (aHUS) - hematopoietic stem cell transplant (HSCT)-associated TMA - thrombotic thrombocytopenic purpura (TTP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) BE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002988-16 | Sponsor Protocol Number: MINT-2014-01 | Start Date*: 2015-07-01 | |||||||||||
Sponsor Name:Royal College of Surgeons in Ireland | |||||||||||||
Full Title: The Use of Milrinone in Neonates with Persistent Pulmonary Hypertension of the Newborn: A Randomised Controlled Trial Pilot Study (MINT 1) | |||||||||||||
Medical condition: Persistent Pulmonary Hypertension of the Newborn | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
